DHR

Danaher Corp

Foreign stocks · NYSE · Healthcare · Life sciences tools and technology

Held by 8 funds8 open to buy3 AMCs

Last close (USD)234.50+4.39 (+1.91%)as of 4 Nov 2026

Funds that hold it8One fund per scheme

Held through a master fund80 buy the stock themselves

Largest weight in a single fund2.96%Of that fund's NAV

Median weight2.90%Half the funds hold more than this

What does DHR do

Danaher Corp

Makes instruments, reagents and software for life science research, biopharmaceutical production and diagnostic labs worldwide

CepheidBeckman CoulterLeica BiosystemsCytivaPall

Where the revenue comes from, and how much is left as profit (FY2025)

For every 100 dollars of sales: cost of sales 41 · operating expenses 40 · tax and other items 4 · leaving 15 as net profit

Which funds let you invest in DHR

Sorted by weight held, largest first

Investors in Thailand can buy DHR through 8 mutual funds open to retail investors. Most of them (8 funds) don't buy the stock themselves. Instead they invest in a master fund abroad, which in turn holds DHR.

Fund	DHR weight	How it invests	1-year return
K-GHEALTHK Global Healthcare Equity Fund	2.96%	Via JPMorgan Funds – Global Healthcare Fund, Class A (acc) - USD	+16.26%
K-GHRMFK Global Healthcare Equity RMF	2.96%	Via JPMorgan Funds – Global Healthcare Fund, Class A (acc) - USD	+16.44%
AFMOATHRMFAF US WIDE MOAT HEDGE RETIREMENT MUTUAL FUND	2.92%	Via MOAT	+7.77%
AFMOAT-HAAF US Wide MOAT Fund Hedged	2.92%	Via MOAT	+8.39%
KFHHCARE-AKrungsri Global Healthcare Equity Hedged FX Fund	2.89%	Via JPMorgan Funds - Global Healthcare Fund	+15.06%
KFHCARERMFKrungsri Global Healthcare Equity RMF	2.88%	Via JPMorgan Funds - Global Healthcare Fund	+15.68%
KFHEALTH-AKrungsri Global Healthcare Equity Fund	2.87%	Via JPMorgan Funds - Global Healthcare Fund	+23.48%
K-GHEALTH(UH)K Global Healthcare Equity Unhedged Fund	2.81%	Via JPMorgan Funds – Global Healthcare Fund, Class A (acc) - USD	+22.56%

Showing 8 of 8 funds you can buy · The full list is in the Expert view · Latest weights from portfolio reports, and funds can change their portfolios at any time · Past performance is not a guarantee of future performance

Want DHR with a tax deduction?

Tax deductions with funds →

DHR share price

0.00%

Price change over the selected periodN/A

50-day average
200-day average

Valuation and key ratios

Danaher Corp · NYSE · Fiscal year ends in January

Market cap164.9B USD0.70 billion shares

P/E46.4xPrice ÷ FY2025 EPS 5.05

Forward P/E24.6xBased on forecast 12-month earnings

P/S6.4x

EV/EBITDA23.4x

Dividend yield0.65%1.52 USD per share a year

ROE7.1%Net profit ÷ shareholders' equity

Debt to equity (D/E)0.35xInterest-bearing debt

Beta0.78Against the S&P 500

Gross margin59.1%FY2025

Operating margin19.1%FY2025

Net margin14.7%FY2025

Price ratios use the latest close shown on this page · Forward P/E, P/S and EV/EBITDA from Market data · Beta from 5 years of monthly returns · Total dividends over the last 12 months

Company health made simple

From the FY2025 statements

Sales growth−0.2%Slow growth

Yearly average over the last 4 years · Latest annual sales 24.6B USD

Profit from sales15%Moderate

For every 100 dollars of sales, about 15 dollars is left as net profit

Dividend0.65%Pays dividends

Per year, relative to the share price · Tech stocks tend to pay little because they reinvest their profits

1-year share price+9.7%Up

Now 3.1% below its 1-year high

A rise or fall in the share price doesn't move a fund by the same amount — a fund is affected only in proportion to how much it holds

Financial statements

Revenue grows −0.2% a year on average · EPS grows −12.5% a year on average

Annual · last 5 fiscal years

FY202124.8B USD6.4B USD

FY202226.6B USD7.2B USD

FY202323.9B USD4.8B USD

FY202423.9B USD3.9B USD

FY202524.6B USD3.6B USD

Total revenue
Net profit

Quarterly · last 5 quarters

Q2 FY20255.9B USD555.0M USD

Q3 FY20256.1B USD908.0M USD

Q4 FY20256.8B USD1.2B USD

Q1 FY20266.0B USD1.0B USD

Q2 FY20266.3B USD870.0M USD

Total revenue
Net profit

Annual income statement, balance sheet and cash flow

Item (USD)	FY2021	FY2022	FY2023	FY2024	FY2025
Total revenue	24.8B USD	26.6B USD	23.9B USD	23.9B USD	24.6B USD
Gross profit	15.2B USD	16.2B USD	14.0B USD	14.2B USD	14.5B USD
Operating profit	6.4B USD	7.5B USD	5.2B USD	4.9B USD	4.7B USD
Net profit	6.4B USD	7.2B USD	4.8B USD	3.9B USD	3.6B USD
EPS (diluted)	8.61	9.66	6.38	5.29	5.05
Gross margin	61.4%	60.8%	58.7%	59.5%	59.1%
Operating margin	25.7%	28.3%	21.8%	20.4%	19.1%
Net margin	25.9%	27.1%	19.9%	16.3%	14.7%
Operating cash flow	8.4B USD	8.5B USD	7.2B USD	6.7B USD	6.4B USD
Free cash flow	7.1B USD	7.4B USD	5.8B USD	5.3B USD	5.3B USD
Total assets	83.2B USD	84.4B USD	84.5B USD	77.5B USD	83.5B USD
Total liabilities	38.0B USD	34.3B USD	31.0B USD	28.0B USD	30.9B USD
Shareholders' equity	45.2B USD	50.1B USD	53.5B USD	49.6B USD	52.5B USD

Free cash flow = operating cash flow − capital expenditure · A cell showing N/A is an item the statement doesn't report, not a zero · Source: SEC EDGAR

Technical analysis

Closed at 234.50 USD on 4 Nov 2026

Daily trendClear uptrendScore 1.00 on a scale of −1 to +1 · 1255 bars

RSI(14): 59.3
ADX(14): 33.4
Position in the price range: 93%

Weekly trendClear uptrendScore 1.00 on a scale of −1 to +1 · 262 bars

RSI(14): 63.7
ADX(14): 18.8
Position in the price range: 91%

Monthly trendClear uptrendScore 0.50 on a scale of −1 to +1 · 61 bars

RSI(14): 57.2
ADX(14): 22.5
Position in the price range: 61%

Moving averages (daily)

Period	SMA	EMA	Price vs line
10 days	232.11	231.33	Above
20 days	228.51	228.60	Above
50 days	219.71	220.80	Above
100 days	208.27	212.44	Above
200 days	201.02	207.49	Above

Indicators (daily)

Indicator	Value	Signal
RSI(14)	59.30	Up
MACD(12,26)	3.92	Up
ADX(14)	33.45	Neutral
ATR(14) % of price	1.39	Neutral

Support and resistance (weekly pivots)

s3223

s2227

s1229

p233

r1236

r2240

r3242

Trend score = average of the moving-average group and the indicator group ((up signals − down signals) ÷ number of signals) · RSI and ATR use Wilder's method · MACD uses the 12- and 26-period EMA · An ADX of 25 or above counts as a clear trend · Calculated from daily closing prices from Market data · Not investment advice

Thai funds holding DHR

8 funds · Highest 2.96% · Median 2.90%

How the weights are spread

< 1%1–3%3–5%5–8%8–12%12%+

The many funds holding less than 3% are usually index funds holding at market weight · Funds holding more than 8% have deliberately chosen a large position

How many funds each AMC holds it through

KASSET3
KSAM3
TALISAM2

Fund	DHR weight	Master fund	1-year return	TER
K-GHEALTH	2.96%	JPMorgan Funds – Global Healthcare Fund, Class A (acc) - USD	+16.26%	1.75%
K-GHRMF	2.96%	JPMorgan Funds – Global Healthcare Fund, Class A (acc) - USD	+16.44%	1.74%
AFMOATHRMF	2.92%	MOAT	+7.77%	2.14%
AFMOAT-HA	2.92%	MOAT	+8.39%	1.93%
KFHHCARE-A	2.89%	JPMorgan Funds - Global Healthcare Fund	+15.06%	1.54%
KFHCARERMF	2.88%	JPMorgan Funds - Global Healthcare Fund	+15.68%	1.54%
KFHEALTH-A	2.87%	JPMorgan Funds - Global Healthcare Fund	+23.48%	1.53%
K-GHEALTH(UH)	2.81%	JPMorgan Funds – Global Healthcare Fund, Class A (acc) - USD	+22.56%	1.76%

One fund counted per scheme · Funds investing through a master fund show the master fund's weight in DHR, not the look-through weight · Past performance is not a guarantee of future performance

How Thai money reaches DHR

3 master funds

Master fund	Thai funds using this route	Master fund's DHR weight
JPMorgan Funds – Global Healthcare Fund, Class A (acc) - USD	3	2.96%
JPMorgan Funds - Global Healthcare Fund	3	2.89%
VanEck Morningstar Wide Moat ETF	2	2.92%

Data sourcesFunds that buy the stock themselves: top 5 holdings from the AMC's fact sheet as of 30 Sep 2026 · Funds that invest through a master fund: the master fund's portfolio from its issuer's fact sheet or prospectus · Each scheme counts as one fund · Share price: Market data · Financial statements: SEC EDGAR · Ratios: Market data · Revenue by business segment: SEC EDGAR · Weights are as of the report date, and funds can change their portfolios at any time · Investing involves risk. This is not investment advice.

Compare

DHR

Danaher Corp

Foreign stocks · NYSE · Healthcare · Life sciences tools and technology

Held by 8 funds8 open to buy3 AMCs

Last close (USD)234.50+4.39 (+1.91%)as of 4 Nov 2026

Funds that hold it8One fund per scheme

Held through a master fund80 buy the stock themselves

Largest weight in a single fund2.96%Of that fund's NAV

Median weight2.90%Half the funds hold more than this

What does DHR do

Danaher Corp

Makes instruments, reagents and software for life science research, biopharmaceutical production and diagnostic labs worldwide

CepheidBeckman CoulterLeica BiosystemsCytivaPall

Where the revenue comes from, and how much is left as profit (FY2025)

For every 100 dollars of sales: cost of sales 41 · operating expenses 40 · tax and other items 4 · leaving 15 as net profit

Which funds let you invest in DHR

Sorted by weight held, largest first

Fund	DHR weight	How it invests	1-year return
K-GHEALTHK Global Healthcare Equity Fund	2.96%	Via JPMorgan Funds – Global Healthcare Fund, Class A (acc) - USD	+16.26%
K-GHRMFK Global Healthcare Equity RMF	2.96%	Via JPMorgan Funds – Global Healthcare Fund, Class A (acc) - USD	+16.44%
AFMOATHRMFAF US WIDE MOAT HEDGE RETIREMENT MUTUAL FUND	2.92%	Via MOAT	+7.77%
AFMOAT-HAAF US Wide MOAT Fund Hedged	2.92%	Via MOAT	+8.39%
KFHHCARE-AKrungsri Global Healthcare Equity Hedged FX Fund	2.89%	Via JPMorgan Funds - Global Healthcare Fund	+15.06%
KFHCARERMFKrungsri Global Healthcare Equity RMF	2.88%	Via JPMorgan Funds - Global Healthcare Fund	+15.68%
KFHEALTH-AKrungsri Global Healthcare Equity Fund	2.87%	Via JPMorgan Funds - Global Healthcare Fund	+23.48%
K-GHEALTH(UH)K Global Healthcare Equity Unhedged Fund	2.81%	Via JPMorgan Funds – Global Healthcare Fund, Class A (acc) - USD	+22.56%

Want DHR with a tax deduction?

Tax deductions with funds →

DHR share price

0.00%

Price change over the selected periodN/A

50-day average
200-day average

Valuation and key ratios

Danaher Corp · NYSE · Fiscal year ends in January

Market cap164.9B USD0.70 billion shares

P/E46.4xPrice ÷ FY2025 EPS 5.05

Forward P/E24.6xBased on forecast 12-month earnings

P/S6.4x

EV/EBITDA23.4x

Dividend yield0.65%1.52 USD per share a year

ROE7.1%Net profit ÷ shareholders' equity

Debt to equity (D/E)0.35xInterest-bearing debt

Beta0.78Against the S&P 500

Gross margin59.1%FY2025

Operating margin19.1%FY2025

Net margin14.7%FY2025

Price ratios use the latest close shown on this page · Forward P/E, P/S and EV/EBITDA from Market data · Beta from 5 years of monthly returns · Total dividends over the last 12 months

Company health made simple

From the FY2025 statements

Sales growth−0.2%Slow growth

Yearly average over the last 4 years · Latest annual sales 24.6B USD

Profit from sales15%Moderate

For every 100 dollars of sales, about 15 dollars is left as net profit

Dividend0.65%Pays dividends

Per year, relative to the share price · Tech stocks tend to pay little because they reinvest their profits

1-year share price+9.7%Up

Now 3.1% below its 1-year high

A rise or fall in the share price doesn't move a fund by the same amount — a fund is affected only in proportion to how much it holds

Financial statements

Revenue grows −0.2% a year on average · EPS grows −12.5% a year on average

Annual · last 5 fiscal years

FY202124.8B USD6.4B USD

FY202226.6B USD7.2B USD

FY202323.9B USD4.8B USD

FY202423.9B USD3.9B USD

FY202524.6B USD3.6B USD

Total revenue
Net profit

Quarterly · last 5 quarters

Q2 FY20255.9B USD555.0M USD

Q3 FY20256.1B USD908.0M USD

Q4 FY20256.8B USD1.2B USD

Q1 FY20266.0B USD1.0B USD

Q2 FY20266.3B USD870.0M USD

Total revenue
Net profit

Annual income statement, balance sheet and cash flow

Item (USD)	FY2021	FY2022	FY2023	FY2024	FY2025
Total revenue	24.8B USD	26.6B USD	23.9B USD	23.9B USD	24.6B USD
Gross profit	15.2B USD	16.2B USD	14.0B USD	14.2B USD	14.5B USD
Operating profit	6.4B USD	7.5B USD	5.2B USD	4.9B USD	4.7B USD
Net profit	6.4B USD	7.2B USD	4.8B USD	3.9B USD	3.6B USD
EPS (diluted)	8.61	9.66	6.38	5.29	5.05
Gross margin	61.4%	60.8%	58.7%	59.5%	59.1%
Operating margin	25.7%	28.3%	21.8%	20.4%	19.1%
Net margin	25.9%	27.1%	19.9%	16.3%	14.7%
Operating cash flow	8.4B USD	8.5B USD	7.2B USD	6.7B USD	6.4B USD
Free cash flow	7.1B USD	7.4B USD	5.8B USD	5.3B USD	5.3B USD
Total assets	83.2B USD	84.4B USD	84.5B USD	77.5B USD	83.5B USD
Total liabilities	38.0B USD	34.3B USD	31.0B USD	28.0B USD	30.9B USD
Shareholders' equity	45.2B USD	50.1B USD	53.5B USD	49.6B USD	52.5B USD

Free cash flow = operating cash flow − capital expenditure · A cell showing N/A is an item the statement doesn't report, not a zero · Source: SEC EDGAR

Technical analysis

Closed at 234.50 USD on 4 Nov 2026

Daily trendClear uptrendScore 1.00 on a scale of −1 to +1 · 1255 bars

RSI(14): 59.3
ADX(14): 33.4
Position in the price range: 93%

Weekly trendClear uptrendScore 1.00 on a scale of −1 to +1 · 262 bars

RSI(14): 63.7
ADX(14): 18.8
Position in the price range: 91%

Monthly trendClear uptrendScore 0.50 on a scale of −1 to +1 · 61 bars

RSI(14): 57.2
ADX(14): 22.5
Position in the price range: 61%

Moving averages (daily)

Period	SMA	EMA	Price vs line
10 days	232.11	231.33	Above
20 days	228.51	228.60	Above
50 days	219.71	220.80	Above
100 days	208.27	212.44	Above
200 days	201.02	207.49	Above

Indicators (daily)

Indicator	Value	Signal
RSI(14)	59.30	Up
MACD(12,26)	3.92	Up
ADX(14)	33.45	Neutral
ATR(14) % of price	1.39	Neutral

Support and resistance (weekly pivots)

s3223

s2227

s1229

p233

r1236

r2240

r3242

Thai funds holding DHR

8 funds · Highest 2.96% · Median 2.90%

How the weights are spread

< 1%1–3%3–5%5–8%8–12%12%+

The many funds holding less than 3% are usually index funds holding at market weight · Funds holding more than 8% have deliberately chosen a large position

How many funds each AMC holds it through

KASSET3
KSAM3
TALISAM2

Fund	DHR weight	Master fund	1-year return	TER
K-GHEALTH	2.96%	JPMorgan Funds – Global Healthcare Fund, Class A (acc) - USD	+16.26%	1.75%
K-GHRMF	2.96%	JPMorgan Funds – Global Healthcare Fund, Class A (acc) - USD	+16.44%	1.74%
AFMOATHRMF	2.92%	MOAT	+7.77%	2.14%
AFMOAT-HA	2.92%	MOAT	+8.39%	1.93%
KFHHCARE-A	2.89%	JPMorgan Funds - Global Healthcare Fund	+15.06%	1.54%
KFHCARERMF	2.88%	JPMorgan Funds - Global Healthcare Fund	+15.68%	1.54%
KFHEALTH-A	2.87%	JPMorgan Funds - Global Healthcare Fund	+23.48%	1.53%
K-GHEALTH(UH)	2.81%	JPMorgan Funds – Global Healthcare Fund, Class A (acc) - USD	+22.56%	1.76%

One fund counted per scheme · Funds investing through a master fund show the master fund's weight in DHR, not the look-through weight · Past performance is not a guarantee of future performance

How Thai money reaches DHR

3 master funds

Master fund	Thai funds using this route	Master fund's DHR weight
JPMorgan Funds – Global Healthcare Fund, Class A (acc) - USD	3	2.96%
JPMorgan Funds - Global Healthcare Fund	3	2.89%
VanEck Morningstar Wide Moat ETF	2	2.92%